WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006115951) UBIQUILIN REGULATION OF PRESENILIN ENDOPROTEOLYSIS, AND SUPPRESSION OF POLYGLUTAMINE-INDUCED TOXICITY IN CELLS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/115951    International Application No.:    PCT/US2006/014795
Publication Date: 02.11.2006 International Filing Date: 19.04.2006
IPC:
C07H 21/02 (2006.01), C07H 21/04 (2006.01), C12N 5/00 (2006.01), C12N 5/02 (2006.01)
Applicants: UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTTUTE OFF. OF RESEARCH ADMIN/TECH. DEV. [US/US]; 701 E. Pratt Street, Suite 200, Baltiomre, MD 21202 (US) (For All Designated States Except US).
MONTEIRO, Mervyn, J. [US/US]; (US) (For US Only).
WANG, Hongmin [CN/US]; (US) (For US Only)
Inventors: MONTEIRO, Mervyn, J.; (US).
WANG, Hongmin; (US)
Agent: HULTQUIST, Steven, J.; Intellectual Property/Technology Law, P.O. Box 14329, Research Triangle Park, NC 27709 (US)
Priority Data:
60/673,642 21.04.2005 US
60/706,839 09.08.2005 US
Title (EN) UBIQUILIN REGULATION OF PRESENILIN ENDOPROTEOLYSIS, AND SUPPRESSION OF POLYGLUTAMINE-INDUCED TOXICITY IN CELLS
(FR) REGULATION PAR UBIQUILINE D'ENDOPROTEOLYSE DE PRESENILINE ET SUPPRESSION DE LA TOXICITE INDUITE PAR LE POLYGLUTAMINE DANS DES CELLULES
Abstract: front page image
(EN)Use of ubiquilin is described, including utilization for reducing fragmentation of presenilin 1 and 2 and to modulate ϝ-secretase components, Pen-2 and Nicastrin, as well as utilization for inducing increased levels of ubiquilin to reduce aggregation of polyglutamine expansion proteins known to cause cell toxicity and cell death in subjects suffering from neurodegenerative diseases, such as Huntington's and Alzheimer's diseases.
(FR)La présente invention concerne l'utilisation de l'ubiquiline. Cette invention est utilisée pour réduire la fragmentation de préséniline 1 et 2 et pour moduler des composants $g(g)-sécrétase, Pen-2 et Nicastrine, ainsi que pour induire une augmentation des niveaux d'ubiquiline afin de réduire l'agrégation de protéines d'expansion de polyglutamine qui sont connues pour causer la toxicité cellulaire et la mort cellulaire chez des sujets souffrant de maladies neurodégénératives telles que la maladie de Huntington et la maladie d'Alzheimer.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)